Gefitinib in lung cancer therapy Clinical results, predictive markers of response and future perspectives

被引：9

作者：

Adamo, Vincenzo ^{[1
]}

Franchina, Tindara ^{[1
]}

Adamo, Barbara ^{[1
]}

Denaro, Nerina ^{[1
]}

Gambadauro, Pietro ^{[1
]}

Chiofalo, Giuseppe ^{[1
]}

Scimone, Antonino ^{[1
]}

Caristi, Nicola ^{[1
]}

Russo, Antonio ^{[2
]}

Giordano, Antonio ^{[3
]}

机构：

[1] Univ Policlin G Martino Messina, Dept Human Pathol, Med Oncol & Integrated Therapies Unit, I-98125 Messina, Italy

[2] Univ Policlin Palermo, Med Oncol Unit, Palermo, Italy

[3] Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA

来源：

CANCER BIOLOGY & THERAPY | 2009年 / 8卷 / 03期

关键词：

gefitinib; non-small cell lung cancer (NSCLC); epidermal growth factor receptor (HER1/EGFR); tyrosine kinase inhibitors; target therapy; molecular markers; EGFR mutations; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; PREVIOUSLY TREATED PATIENTS; PHASE-II TRIAL; EGFR MUTATIONS; 2ND-LINE THERAPY; GENE-MUTATIONS; STAGE-IIIB; ZD1839; IRESSA;

D O I：

10.4161/cbt.8.3.7465

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Over the past few years, epidermal growth factor receptor has emerged as one of the most important targets in tumorgenesis and several drugs targeting signal transduction pathways have been developed. The first among these agents to be approved for the treatment of NSCLC was gefitinib, a potent, selective and reversible inhibitor of HER1/EGFR tyrosine kinase activity. The review summarizes its clinical development and the new therapeutic options, with particular focus on predictive markers of susceptibility to this drug.

引用

页码：202 / 208

页数：7

共 49 条

[1]

[Anonymous], 2007, INVESTIGATORS BROCHU, V01

[2]

Bailey R., 2003, LUNG CANCER, V41, ps71, DOI [10.1016/S0169-5002(03)91900-3, DOI 10.1016/S0169-5002(03)91900-3]

[3] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[4] Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials [J].

Bell, DW ;

Lynch, TJ ;

Haserlat, SM ;

Harris, PL ;

Okimoto, RA ;

Brannigan, BW ;

Sgroi, DC ;

Muir, B ;

Riemenschneider, MJ ;

Iacona, RB ;

Krebs, AD ;

Johnson, DH ;

Giaccone, G ;

Herbst, RS ;

Manegold, C ;

Fukuoka, M ;

Kris, MG ;

Baselga, J ;

Ochs, JS ;

Haber, DA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8081-8092

[5]

Brabender J, 2001, CLIN CANCER RES, V7, P1850

[6]

Brehmer D, 2005, CANCER RES, V65, P379

[7] Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients [J].

Cappuzzo, F ;

Varella-Garcia, M ;

Shigematsu, H ;

Domenichini, I ;

Bartolini, S ;

Ceresoli, GL ;

Rossi, E ;

Ludovini, V ;

Gregorc, V ;

Toschi, L ;

Franklin, WA ;

Crino, L ;

Gazdar, AF ;

Bunn, RA ;

Hirsch, FR .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5007-5018

[8] Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer [J].

Cappuzzo, F ;

Magrini, E ;

Ceresoli, GL ;

Bartolini, S ;

Rossi, E ;

Ludovini, V ;

Gregorc, V ;

Ligorio, C ;

Cancellieri, A ;

Damiani, S ;

Spreafico, A ;

Paties, CT ;

Lombardo, L ;

Calandri, C ;

Bellezza, G ;

Tonato, M ;

Crinò, L .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) :1133-1141

[9]

CAPPUZZO F, 2003, LUNG CANCER, V41, P183

[10] Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study [J].

Chang, Alex ;

Parikh, Purvish ;

Thongprasert, Sumitra ;

Tan, Eng Huat ;

Perng, Reury- Perng ;

Ganzon, Domingo ;

Yang, Chih-Hsin ;

Tsao, Chao-Jung ;

Watkins, Claire ;

Botwood, Nick ;

Thatcher, Nick .

JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (08) :847-855

← 1 2 3 4 5 →